Brief: Inhibikase Therapeutics Announces Development Of Novel Formulation Of Risvodetinib
24/08/2023 13:33
Aug 24 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES DEVELOPMENT OF NOVEL
FORMULATION OF RISVODETINIB
* INHIBIKASE THERAPEUTICS INC - TABLET FORMULATION TO BE
EVALUATED
IN PLANNED 12-MONTH EXTENSION PORTION OF 201 TRIAL
Source text for Eikon: ID:nPn33tFppa
Further company coverage: IKT.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary